Targeting the unmet medical need: The Abbott Laboratories oncology approach

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 9, 2005, Pages 703-710

  Carlson, Dawn M ^a   Steinberg, Joyce L ^b   Gordon, Gary ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; APOPTOSIS INDUCING FACTOR; ATRASENTAN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ENDOTHELIN A RECEPTOR ANTAGONIST; EPOTHILONE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEUPRORELIN; MACROGOL; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG TARGETING; FATIGUE; HEADACHE; HEART FAILURE; HUMAN; ILEUS; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; MAXIMUM PERMISSIBLE DOSE; METASTASIS; NEUROPATHY; NONHUMAN; PAIN; PERIPHERAL EDEMA; RHINITIS; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUG EVALUATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 29244453923     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10-30.
2. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110-116.
3. Yanagisawa M, Kurihara H, Kimura. S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
4. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863-2867.
5. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin 1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
6. Nelson JB, Chan Tack K, Hedican SP, et al. Endothelin 1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663-668.
7. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-949.
8. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 2000;60:5310-5317.
9. Wu-Wong JR, Chiou WJ, Wang J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J Pharmacol Exp Ther. 2000;293:514-521.
10. Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci. 2002; 103(suppl 48):306S-309S.
11. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin 1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol. 2002;61:524-532.
12. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88:163-166.
13. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999;53:1063-1069.
14. Guise TA, Yin JJ, Mohammad KS. Role of endothelin 1 in osteoblastic bone metastases. Cancer. 2003;97(suppl 3):779-784.
15. Yin JJ, Mohammad KS, Käkönen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954-10959.
16. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21-28.
17. Chirgwin JM, Guise TA. Cancer metastasis to bone. Sci Med. 2003;9:140-151.
18. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003;9:2587-2597.
19. Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs. 2004;13:1631-1640.
20. Raffa RB, Schupsky JJ, Martinez RP, Jacoby HI. Endothelin-1-induced nociception. Life Sci. 1991;49:PL61-PL65.
21. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci. 2001;21:5358-5366.
22. Sabino MAC, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol. 2005;3:15-24.
23. Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metabol. 1992;74:223-225.
24. Kobayashi S, Tang R, Wang B, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151:763-766.
25. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen independent progression. Nat Med. 1998;4:50-57.
26. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor A associated with prostate cancer progression. J Urol. 2001;165:1033-1036.
27. Verhaar MC, Grahn AY, van Weerdt AW, et al. Pharmacokinetics and pharmacodynamic effects of ABT 627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol. 2000;49:562-573.
28. Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ. Single dose pharmacokinetics of atrasentan, an endothelin A receptor antagonist. J Clin Pharmacol. 2001;41:397-403.
29. Dutta S, Samara E, Lam W, Granneman GR, Leese PT, Padley RJ. Multiple dose pharmacokinetics of atrasentan, an endothelin A receptor antagonist. Clin Drug Invest. 2001;21:129-136.
30. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer; a randomized, phase II, placebo controlled trial. J Clin Oncol. 2003;21:679-689.
31. Honing MLH, Hijmering ML, Ballard DE, et al. Selective ETA receptor antagonism with ABT 627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol. 2000;11:1498-1504.
32. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002;20:2171 2180.
33. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Underia SD, Humerickhouse RA, et al. Dose ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004; 10:4406-4411.
34. Lassiter LK, Carducci MA. Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol. 2003;30:678-688.
35. Phuphanich S, Carson K, Grossman S, et al. A phase I evaluation of the safety of escalating doses of atrasentan in adults with recurrent malignant glioma [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):120s. Abstract 1526.
36. Jones A, Harris AL. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J Sci Am. 1998;4:209-217.
37. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13:159-167.
38. Fidler IJ, Kerbel RS, Ellis LM. Biology of cancer: angiogenesis. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:139-140.
39. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface expressed glucose regulated protein 78. Cancer Res. 2005;65:4663-4672.
40. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3:1222-1227.
41. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12.
42. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem. 2005;48:2838-2846.
43. Lawler J. The structural and functional properties of thrombospondin. Blood. 1986;67:1197-1209.
44. Dawson DW, Volpert OV, Pearce SFA, Schneider AJ, Silverstein RL, Henkin J, et al. Three distinct D-amino acid substitutions confer potent anti-angiogenic activity on an inactive peptide derived from thrombospondin-1 type 1 repeat. Mol Pharmacol. 1999;55:332-338.
45. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003;22(1):63-71.
46. Watnick RS, Cheng Y, Rangarajan A, Ince TA, Weinberg RA, Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3:219-231.
47. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002;98:682-689.
48. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000;19:597-614.
49. Li Q, Ahuja N, Burger PC, Issa JJ. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene. 1999;18:3284 3289.
50. Bornstein P. Thrombospondins as matricellular modulations of cell function. J Clin Invest. 2001;107:929-939.
51. Hoekstra R, De Vos FYFL, Eskens FALM, et al. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the thrombospondin-1 mimetic angiogenesis inhibitor ABT 510 in patients with advanced cancer. J Clin Oncol. 2005;23:5188-5197.
52. Gordon MS, Mendelson D, Guirguis MS, et al. ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase 1B trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:195. Abstract 780.
53. Baker LH, Demetri GD, Mendelson DS, et al. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT 510 in patients with advanced soft tissue sarcoma (STS) [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):819s. Abstract 9013.
54. Ebbinghaus S, Hussain M, Tannir N, Gordon MS, Desai AA, Knight RA, et al. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT 510 in patients with previously untreated advanced renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):404s. Abstract 4607.
55. Van Glabbeke M, Verweij J, Judson I, Nielsen OS, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group. Progression free rate as the principal end point for phase II trials in soft tissue sarcomas. Eur J Cancer. 2002;38:543-549.
56. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
57. Stirewalt DL, Radich JP. Ihe role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
58. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999-4006.
59. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
60. Camps JL, Chang SM, Hsu TC, et al. Fibroblast mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A. 1990;87:75-79.
61. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
62. Crivellato E, Ribatti D. Involvement of mast cells in angiogenesis and chronic inflammation. Curr Drug Targets Inflam Allergy. 2005;4:9-11.
63. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
64. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
65. Albert DH, Tapang P, Magoc T, et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor [abstract]. Proc Am Assoc Cancer Res. 2005;46:159. Abstract 676.
66. Li J, Pease LJ, Tapang P, et al. ABT-869, a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia [abstract]. Proc Am Assoc Cancer Res. 2005;46:1407. Abstract 5981.
67. Kastan MB, Skapek SX. Molecular biology of cancer: the cell cycle. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:103.
68. Jordan, MA, Wilson L. Use of drugs to study role of microtubule assembly dynamics in living cells. Methods Enzymol. 1998:298:252-276.
69. Raynaud FI, Judson IR. Synthetic microtubule inhibitors. Drugs Future. 1996;21:65-70.
70. Li Q, Sham HL, Rosenberg SH. Antimitotic Agents. In: Doherty A, ed. Ann Reports in Med Chem, Volume 34. UK: Academic Press; 1999:139-148.
71. Wilson L, Jordan MA. Pharmacological probes of microtubular function. In: Hyams J, Lloyd C. eds. Microtubules. New York, NY: John Wiley and Sons, Inc.; 1994:59-84.
72. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325-2333.
73. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. 1994;54:1702-1706.
74. Yamamoto K, Noda, K, Yoshimura A, Fukuoka M, Furuse K, Nitani H. Phase I study of E7010. Cancer Chemother Pharmacol. 1998;42:127-134.
75. Fox E, Adamson PC, Hagey A, et al. Phase 1 trial of oral ABT-751 in pediatric patients: preliminary evidence of activity in neuroblastoma (NBL) [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):806s. Abstract 8527.
76. Hagey AE, Figlin RA, Moldawer N, et al. Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):403s. Abstract 4603.
77. Benson AB, Kindler HL, Jodrell D, et al. Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC) [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):255s. Abstract 3537.
78. Washington DK, Storniolo AMV, Saleh M, et al. Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: interim analysis [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):59s. Abstract 724.
79. Mauer AM, Szeto L, Belt RJ, et al. Preliminary results of a phase 2 study of ABT-751 in patients with taxane refractory non-small cell lung carcinoma [abstract]. Proc Am Soc Clin Oncol. 2005;23(17s):654s. Abstract 7137.
80. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
81. Ji WR, Barrientos LG, Llinas M, et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun. 1998;247:414-419.
82. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl 2 family proteins induces regression of solid tumors. Nature. 2005;435;677-681.
83. Southa GJ and Szabo C. Poly(ADP-Ribose) polymerase inhibitors. Current Medicinal Chemistry. 2003;10:321-340.